Journals / Bozok Tıp Dergisi / 2014 / Cilt: 4 - Sayı: 1

Non Alcoholic Fatty Liver Disease In Children

ÇOCUKLARDA ALKOLİK OLMAYAN YAĞLI KARACİĞER HASTALIĞI Non Alcoholic Fatty Liver Disease In Children

Pages
55–61
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cirrhosis is seen in 7-16% of patients at the time of liver biopsy. weight reduction and excercising have the most important role in treatment.There is no strict data about drugs for children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Obesity and its complications are increasing with improving lifestyles in our century.
📊
Key Findings & Data:The prevalence of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH) is thought to be more than expected.
💡
Conclusion & Impact:Cirrhosis is seen in 7-16% of patients at the time of liver biopsy. weight reduction and excercising have the most important role in treatment.There is no strict data about drugs for children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Obesity and its complications are increasing with improving lifestyles in our century. The prevalence of non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH) is thought to be more than expected. The diagnosis is particularly made incidentally by finding elevated ALT/AST ratio, enlarged liver on ultrasonographic examination. But on the other hand this disease can lead to cirrhosis during childhood. Liver biopsy is gold-standart if performed among patients who fulfill some suggested criteria. There are no precise data about clinical outcome. Obesity, insülin resistance and dislipidemia are the factors that can lead to worse histolojical findings and poorer prognosis as well. Isolated steatosis has the best prognosis, whereas the prognosis gets worse when fibrosis is added to hepatocyte injury. Cirrhosis is seen in 7-16% of patients at the time of liver biopsy. weight reduction and excercising have the most important role in treatment.There is no strict data about drugs for children.

Özet

Gelişen yaşam koşulları ile obezite ve komplikasyonları da artmaktadır. Alkolik Olmayan Yağlı Kara- ciğer Hastalığı (AOYKH)/ Alkolik Olmayan Steatohepatit (AOSH) gerçek prevalansı tahmin edilenin daha üzerindedir. Tanının tesadüfen konulduğu ancak çocukluk çağında nadiren de siroza neden olan bu hastalık, rutin muayene sırasında artmış ALT/AST oranı, ultrason (USG) de belirgin karaci- ğer ile tanınabilir. Karaciğer biyopsisi özellikli hastalarda tanı koymada altın standarttır. Klinik gidiş hakkında net veriler yoktur. Obezite, insülin direnci ve dislipidemi durumlarında histolojik bulgular daha ilerlemiştir ve prognoz daha kötü olabilir. İzole yağlanma en iyi prognoza sahip iken, fibrozisin eşlik ettiği hepatosit hasarı varlığında prognoz daha kötüleşmektedir. Karaciğer biyopsisi sırasında hastaların %7-16sında siroz gelişmiştir. Tedavide kilo verme ve egzersiz en önemli rolü oynamakta- dır. İlaçlar konusunda çocuklarda kesinleşmiş veriler yoktur.

🔖

Cite This Article

KÜÇÜK, Ö., UĞRAŞ, M., VİTRİNEL, A., BİÇER, S. (2022). Non Alcoholic Fatty Liver Disease In Children. Bozok Tıp Dergisi, Cilt: 4 - Sayı: 1, 55–61. https://ajindex.com/articles/468965

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/ NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18 (6):1089-104
  2. Sathya P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002;14 (5):593-600
  3. Leevy C. Fatty Liver. A study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine.1962;41 (1):249-76
  4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non alcoholic steatohepatitis:Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc.1980;55 (7):434-8
  5. Portincasa P, Grattagliano I, Palmieri Vo, Palasciano G. Nonalcoholic steatohepatitis: recent advances fron experimental models to clinical management. Clin Biochem. 2002;38 (3):203-17
  6. Kimm SY, Barton BA, Obarzanek E, McMahon RP, Kronsberg SS, Waclawiw MA, et al. Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics. 2002;110 (5):54
  7. Livingstone B. Epidemiology of childhood obesity in Europe. Eur J Pediatr. 2000;159 (1):14-34
  8. Kanbur NO, Derman O, Kinik E. Prevalence of obesityin adolescents and the impact of sexual maturation stage on body mass index in obese adolescents. Int J Adolesc Med Health. 2002;14 (1):61-5
  9. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78 (6):374-7
  10. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995;127 (5):700-4
  11. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in nonalcoholics;non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn.1992;27 (4):521-8
  12. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology. 1995;108 (5):1607
  13. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98 (5):960-7
  14. Reilly JJ, Dorosty AR. Epidemic of obesity in UK children. Lancet. 1999:354(9193);1874-5
  15. Strauss RS, Barlow SE, Dietz WH: Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136 (6):727-33
  16. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevale